Hyp-dBET1|CAS |DC Chemicals

Cas No.:
Chemical Name:	Hyp-dBET1
SMILES:	CC1=C(C)C(C(C2=CC=C(Cl)C=C2)=N[C@H]3CC(N(CC4=CC=C([N+]([O-])=O)C=C4)CCCCNC(COC5=C6C(C(N(C7C(NC(CC7)=O)=O)C6=O)=O)=CC=C5)=O)=O)=C(S1)N8C3=NN=C8C
Formula:	C₄₅H₄₂ClN₉O₉S
M.Wt:	920.39
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Cat. No.	Product name	Field of application
DC72179	UNC1021	UNC1021 is a selective L3MBTL3 inhibitor with an IC50 of 0.048 μM.
DC71321	ET-JQ1-OH	ET-JQ1-OH is an allele-specific BET inhibitor.
DC48075	SGC-SMARCA-BRDVIII	SGC-SMARCA-BRDVIII is a potent and selective SMARCA2/4 BRD inhibitor.
DC47977	I-BET567	I-BET567 is a potent and oral active inhibitor of pan-BET candidate with pIC50s of 6.9 and 7.2 for BRD4 BD1 and BD2, respectively. I-BET567 has been demonstrated efficacy in mouse models of oncology and inflammation.
DC47894	SR-0813	SR-0813 is a potent and selective ENL/AF9 YEATS domain inhibitor. SR-0813 has IC50 and EC50 values of 25 nM and 205 nM for ENL YEATS domain, respectively. SR-0813 has IC50 and EC50 values of 311 nM and 76 nM (CETSA) for AF9 YEATS domain, respectively. SR-0813 binds MAP3K19 with over 100-fold lower affinity (Kd=3.5 μM) than ENL YEATS (Kd=30 nM). SR-0813 can be used for the research of acute leukemia.
DC46834	Menin-MLL inhibitor 20,MRN73473	Menin-MLL inhibitor 20 is an irreversible menin-MLL interaction inhibitor with antitumor activities (WO2020142557A1, compound 6).
DC42491	GSK778（iBET-BD1 dihydrochloride）	GSK778 (iBET-BD1) is a potent and selective BD1 bromodomain inhibitor of the BET proteins, with IC50s of 75 nM (BRD2 BD1), 41 nM (BRD3 BD1), 41 nM (BRD4 BD1), and 143 nM (BRDT BD1), respectively. GSK778 phenocopies the effects of pan-BET inhibitors in cancer models.
DC42300	GSK620	GSK620 is a potent and orally active pan-BD2 with excellent broad selectivity, developability and in vivo oral pharmacokinetics. GSK620 is highly selective for the BET-BD2 family of proteins, with >200-fold selectivity over all other bromodomains. GSK620
DC41049	Trotabresib (CC-90010)	Trotabresib (CC-90010) is a reversible and orally active BET inhibitor. CC-90010 is applied in the study for advanced solid tumors.
DC39097	NEO2734	NEO2734 (EP31670) is a novel, orally active and selective dual inhibitor of p300/CBP and BET bromodomain with IC50 of both <30 nM.